Israel - hebraisk - Ministry of Health

tzamal bio-pharma ltd - orlistat - קפסולות - orlistat 120 mg - orlistat - orlistat - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.

Israel - hebraisk - Ministry of Health

sanofi israel ltd - agalsidase beta - אבקה להכנת תמיסה מרוכזת לעירוי - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

Israel - hebraisk - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone - medroxyprogesterone - for contraception where medically indicated and oral administration is inapplicable.

Israel - hebraisk - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Israel - hebraisk - Ministry of Health

tzamal bio-pharma ltd - calcitonin salmon 200 iu/dose - nasal spray - calcitonin (salmon synthetic) - fortical® nasal spray is indicated for:postmenopausal osteoporosis – fortical® calcitonin-salmon (rdna origin) nasal spray isindicated for the treatment of postmenopausal osteoporosis in women greater than 5 yearspostmenopause with low bone mass relative to healthy premenopausal women. use of fortical®calcitonin-salmon (rdna origin) nasal spray is recommended in conjunction with an adequatecalcium (at least 1000 mg elemental calcium per day) and vitamin d (400 international units perday) intake to retard the progressive loss of bone mass. the evidence of efficacy for calcitoninsalmonis based on increases in spinal bone mineral density (bmd) observed in clinical trials

Israel - hebraisk - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

Israel - hebraisk - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

Israel - hebraisk - Ministry of Health

sanofi israel ltd - cabazitaxel - תרכיז וממס להכנת תמיסה לאינפוזיה - cabazitaxel 60 mg / 1.5 ml - cabazitaxel - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

Israel - hebraisk - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.